[go: up one dir, main page]
More Web Proxy on the site http://driver.im/

MX2018007390A - Composiciones que comprenden acido 15-hidroxi eicosapentaenoico (15-hepe) y metodos de uso del mismo. - Google Patents

Composiciones que comprenden acido 15-hidroxi eicosapentaenoico (15-hepe) y metodos de uso del mismo.

Info

Publication number
MX2018007390A
MX2018007390A MX2018007390A MX2018007390A MX2018007390A MX 2018007390 A MX2018007390 A MX 2018007390A MX 2018007390 A MX2018007390 A MX 2018007390A MX 2018007390 A MX2018007390 A MX 2018007390A MX 2018007390 A MX2018007390 A MX 2018007390A
Authority
MX
Mexico
Prior art keywords
hepe
compositions
methods
same
relates
Prior art date
Application number
MX2018007390A
Other languages
English (en)
Other versions
MX379262B (es
Inventor
Coughlan David
Climax John
Original Assignee
Afimmune Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Afimmune Ltd filed Critical Afimmune Ltd
Publication of MX2018007390A publication Critical patent/MX2018007390A/es
Publication of MX379262B publication Critical patent/MX379262B/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/20—Carboxylic acids, e.g. valproic acid having a carboxyl group bound to a chain of seven or more carbon atoms, e.g. stearic, palmitic, arachidic acids
    • A61K31/202—Carboxylic acids, e.g. valproic acid having a carboxyl group bound to a chain of seven or more carbon atoms, e.g. stearic, palmitic, arachidic acids having three or more double bonds, e.g. linolenic
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
    • A61K31/215—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
    • A61K31/22—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acyclic acids, e.g. pravastatin
    • A61K31/23—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acyclic acids, e.g. pravastatin of acids having a carboxyl group bound to a chain of seven or more carbon atoms
    • A61K31/232—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acyclic acids, e.g. pravastatin of acids having a carboxyl group bound to a chain of seven or more carbon atoms having three or more double bonds, e.g. etretinate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/48—Drugs for disorders of the endocrine system of the pancreatic hormones
    • A61P5/50—Drugs for disorders of the endocrine system of the pancreatic hormones for increasing or potentiating the activity of insulin

Landscapes

  • Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • Diabetes (AREA)
  • Emergency Medicine (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Endocrinology (AREA)
  • Rheumatology (AREA)
  • Obesity (AREA)
  • Hematology (AREA)
  • Pulmonology (AREA)
  • Pain & Pain Management (AREA)
  • Dermatology (AREA)
  • Reproductive Health (AREA)
  • Psychology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Child & Adolescent Psychology (AREA)
  • Psychiatry (AREA)
  • Hospice & Palliative Care (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Immunology (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)

Abstract

La presente invención se refiere a las composiciones que comprenden 15-HEPE y a métodos de tratamiento relacionados con las mismas.
MX2018007390A 2015-12-18 2016-12-19 Composiciones que comprenden acido 15-hidroxi eicosapentaenoico (15-hepe) y metodos de uso del mismo. MX379262B (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201562269280P 2015-12-18 2015-12-18
PCT/IB2016/001878 WO2017103671A1 (en) 2015-12-18 2016-12-19 Compositions comprising 15-hepe and methods of using the same

Publications (2)

Publication Number Publication Date
MX2018007390A true MX2018007390A (es) 2018-11-09
MX379262B MX379262B (es) 2025-03-10

Family

ID=57995240

Family Applications (2)

Application Number Title Priority Date Filing Date
MX2021000773A MX394051B (es) 2015-12-18 2016-12-19 Composiciones que comprenden acido 15-hidroxieicosapentaenoico (15-hepe) y metodos de uso del mismo
MX2018007390A MX379262B (es) 2015-12-18 2016-12-19 Composiciones que comprenden acido 15-hidroxi eicosapentaenoico (15-hepe) y metodos de uso del mismo.

Family Applications Before (1)

Application Number Title Priority Date Filing Date
MX2021000773A MX394051B (es) 2015-12-18 2016-12-19 Composiciones que comprenden acido 15-hidroxieicosapentaenoico (15-hepe) y metodos de uso del mismo

Country Status (18)

Country Link
US (4) US9855238B2 (es)
EP (2) EP4218736A3 (es)
JP (4) JP2018537513A (es)
KR (5) KR20230047501A (es)
CN (2) CN113230244A (es)
AR (1) AR107143A1 (es)
AU (4) AU2016370626B2 (es)
BR (1) BR122023026625A2 (es)
CA (2) CA3008774C (es)
ES (1) ES2948444T3 (es)
IL (3) IL294736A (es)
MX (2) MX394051B (es)
NZ (3) NZ783466A (es)
PH (1) PH12018501279A1 (es)
RU (2) RU2020137883A (es)
SG (1) SG11201805149XA (es)
WO (1) WO2017103671A1 (es)
ZA (2) ZA201804779B (es)

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB201301626D0 (en) * 2013-01-30 2013-03-13 Dignity Sciences Ltd Composition comprising 15-OHEPA and methods of using the same
US10017453B2 (en) 2013-11-15 2018-07-10 Ds Biopharma Limited Pharmaceutically acceptable salts of fatty acids
MA41120A (fr) 2014-12-02 2017-10-10 Afimmune Ltd Compositions comprenant le 15-hepe et méthodes de traitement ou de prévention de la fibrose à l'aide de celles-ci
CN107847477A (zh) 2015-05-13 2018-03-27 Ds生物制药有限公司 包含15‑氧代‑epa或15‑氧代‑dgla的组合物及其制备和使用方法
CN112245420A (zh) 2015-07-21 2021-01-22 艾菲穆恩有限公司 用于治疗或预防癌症和神经疾病的包括15-hepe的组合物
ES2948444T3 (es) * 2015-12-18 2023-09-12 Afimmune Ltd Composiciones que comprenden 15-HEPE
CN113116878A (zh) * 2020-01-10 2021-07-16 南京大学 15s-hepe用于增强t细胞介导的肿瘤免疫治疗的新用途
US20210315851A1 (en) 2020-04-03 2021-10-14 Afimmune Limited Compositions comprising 15-hepe and methods of treating or preventing hematologic disorders, and/or related diseases
US11622495B2 (en) 2021-06-01 2023-04-11 Gint Co., Ltd. Method of automatically combining farm vehicle and work machine and farm vehicle
CN113855659B (zh) * 2021-11-24 2022-12-23 中国人民解放军东部战区总医院 12-hepe或其药学上可接受的脂肪酸改善精子发生障碍的应用

Family Cites Families (46)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPH05186342A (ja) 1992-01-10 1993-07-27 Fujirebio Inc 免疫調節作用を併せもつ抗炎症剤
GB9301446D0 (en) 1993-01-26 1993-03-17 Scotia Holdings Plc Internal radiation damage
AU683027B2 (en) 1993-01-27 1997-10-30 Scotia Holdings Plc Triglycerides
EP0838216A1 (en) 1993-10-01 1998-04-29 R.P. Scherer Corporation Methods and compositions for dispensing fragrances
GB9715444D0 (en) 1997-07-22 1997-09-24 Scotia Holdings Plc Therapeutic and dietary compositions
JP2000191525A (ja) 1998-12-25 2000-07-11 Nof Corp 皮膚外用剤組成物
US6670396B2 (en) 2000-02-16 2003-12-30 Brigham And Women's Hospital Aspirin-triggered lipid mediators
US20020188024A1 (en) 2000-08-23 2002-12-12 Chilton Floyd H. Fatty acid-containing emulsion with increased bioavailability
US20040043013A1 (en) 2000-12-28 2004-03-04 Mccleary Edward Larry Metabolic uncoupling therapy
WO2002096408A1 (en) 2001-05-30 2002-12-05 Laxdale Limited Coenzyme q and eicosapentaenoic acid (epa)
WO2004048497A1 (ja) 2002-11-22 2004-06-10 Nippon Suisan Kaisha, Ltd. 高度不飽和脂肪酸、その塩、またはそのエステルを含有する外用組成物
JP2005179211A (ja) 2003-12-17 2005-07-07 Idemitsu Kosan Co Ltd 皮膚外用剤組成物
GB2409644B (en) 2003-12-31 2005-12-21 Igennus Ltd Formulation comprising eicosapentaenoic acid or an ester thereof and a triterpene or an ester thereof
WO2005102309A2 (en) 2004-04-26 2005-11-03 Ltb4 Sweden Ab In vivo release of endogenous anti-microbial mediators by leukotriene b4 (ltb4) administration
WO2006007510A1 (en) 2004-07-01 2006-01-19 Schepens Eye Research Compositions and methods for treating eye disorders and conditions
US7666447B2 (en) 2004-10-08 2010-02-23 Pharmanutrients Compositions including Krill extracts and conjugated linoleic acid and methods of using same
US7893106B2 (en) 2004-11-19 2011-02-22 Martek Biosciences, Corporation Oxylipins from stearidonic acid and γ-linolenic acid and methods of making and using the same
JP5504405B2 (ja) * 2005-06-10 2014-05-28 国立大学法人山口大学 血管病予防に効果を有する食品組成物
EP3285072B1 (en) 2006-08-08 2020-04-15 Metabolon, Inc. Markers of non-alcoholic fatty liver disease (nafld) and non-alcoholic steatohepatitis (nash) and methods of use thereof
GB0802116D0 (en) 2008-02-05 2008-03-12 Natural Enviromental Res Counc Treatment
JPWO2009154230A1 (ja) 2008-06-17 2011-12-01 持田製薬株式会社 非アルコール性脂肪肝炎の予防／改善・治療薬
JP2010229099A (ja) * 2009-03-27 2010-10-14 Mochida Pharmaceut Co Ltd 脂質異常症の改善または治療薬
GB0907413D0 (en) 2009-04-29 2009-06-10 Equateq Ltd Novel methods
EP3181131A1 (en) * 2009-05-22 2017-06-21 Mochida Pharmaceutical Co., Ltd. Self-emulsifying compositin of 3 fatty acid
CA2690488C (en) 2010-01-19 2013-06-11 Accucaps Industries Limited Pharmaceutical formulations of naproxen for soft gel encapsulation and combinations thereof
US10154977B2 (en) 2011-03-25 2018-12-18 The Brigham And Women's Hospital, Inc. Anti-inflammatory particles
US20120264824A1 (en) 2011-04-15 2012-10-18 Mochida Pharmaceutical Co., Ltd. Compositions and methods for treating non-alcoholic steatohepatitis
KR20140091690A (ko) 2011-10-19 2014-07-22 디그너티 사이언스 리미티드 Ｄｇｌａ 및/또는 15-ｈｅｔｒｅ을 포함하는 약제학적 조성물 및 그의 사용 방법
US8293790B2 (en) 2011-10-19 2012-10-23 Dignity Sciences Limited Pharmaceutical compositions comprising DGLA and benzoyl peroxide and methods of use thereof
SG11201402653QA (en) 2011-11-29 2014-06-27 Dignity Sciences Ltd Compositions comprising 20-carbon fatty acids and methods of making and using same
KR102153245B1 (ko) 2012-01-06 2020-09-08 옴테라 파마슈티칼스, 인크. 유리 산 형태의 오메가-3 다중불포화 지방산의 ｄｐａ-농축 조성물
US20120264705A1 (en) * 2012-01-26 2012-10-18 Dignity Sciences Limited Antimicrobial compositions comprising 15-hetre and methods of use thereof
US20130267598A1 (en) 2012-02-23 2013-10-10 Dignity Sciences Limited Pharmaceutical compositions comprising dgla, 15-ohepa, and/or 15-hetre and methods of reducing sebum production using same
IN2014DN08449A (es) * 2012-03-30 2015-05-08 Sancilio & Company Inc
WO2013150386A2 (en) 2012-04-04 2013-10-10 Pronova Biopharma Norge As Compositions comprising omega-3 fatty acids and vitamin d for acne vulgaris and/or eczema, and methods and uses thereof
EP4205546A1 (en) * 2012-05-10 2023-07-05 Solutex NA LLC Oils with anti-inflammatory activity containing natural specialized proresolving mediators and their precursors
GB201213484D0 (en) * 2012-07-30 2012-09-12 Dignity Sciences Ltd Pharmaceutical compositions comprising 15-OHEPA and methods of using the same
GB201301626D0 (en) * 2013-01-30 2013-03-13 Dignity Sciences Ltd Composition comprising 15-OHEPA and methods of using the same
EP3023099B1 (en) * 2013-07-18 2020-09-30 Mochida Pharmaceutical Co., Ltd. Self-emulsifying composition of -3 fatty acid
US10017453B2 (en) * 2013-11-15 2018-07-10 Ds Biopharma Limited Pharmaceutically acceptable salts of fatty acids
MX2016008953A (es) * 2014-01-10 2017-02-02 Dignity Sciences Ltd Composiciones farmaceuticas que comprenden i5-hidroxi-eicosa- 5,8,11,13,17-pentaenoico ( 15-hepe ) y metodos para tratar el asma y trastornos pulmonares que usan las mismas.
MA41120A (fr) * 2014-12-02 2017-10-10 Afimmune Ltd Compositions comprenant le 15-hepe et méthodes de traitement ou de prévention de la fibrose à l'aide de celles-ci
JP2018502163A (ja) * 2015-01-16 2018-01-25 アフィミューン リミテッド １５−ｈｅｐｅを含む組成物及びそれを使用する方法
CN107847477A (zh) * 2015-05-13 2018-03-27 Ds生物制药有限公司 包含15‑氧代‑epa或15‑氧代‑dgla的组合物及其制备和使用方法
CN112245420A (zh) * 2015-07-21 2021-01-22 艾菲穆恩有限公司 用于治疗或预防癌症和神经疾病的包括15-hepe的组合物
ES2948444T3 (es) 2015-12-18 2023-09-12 Afimmune Ltd Composiciones que comprenden 15-HEPE

Also Published As

Publication number Publication date
JP2020063259A (ja) 2020-04-23
MX394051B (es) 2025-03-24
CA3008774C (en) 2021-10-12
RU2018126361A (ru) 2020-01-22
US20180104207A1 (en) 2018-04-19
US20170172965A1 (en) 2017-06-22
AR107143A1 (es) 2018-03-28
ZA201804779B (en) 2019-09-25
CA3129008A1 (en) 2017-06-22
AU2020267224B2 (en) 2022-09-29
EP3389647A1 (en) 2018-10-24
EP3389647B1 (en) 2023-04-05
AU2020267224A1 (en) 2020-12-10
ES2948444T3 (es) 2023-09-12
AU2022291628B2 (en) 2025-04-03
AU2022291628A1 (en) 2023-02-02
US10231945B2 (en) 2019-03-19
KR20230047501A (ko) 2023-04-07
RU2020137883A (ru) 2020-12-03
IL294736A (en) 2022-09-01
US9855238B2 (en) 2018-01-02
BR122023026625A2 (pt) 2024-01-16
AU2025201593A1 (en) 2025-03-20
KR20220038818A (ko) 2022-03-29
EP4218736A3 (en) 2023-10-18
ZA202104969B (en) 2023-01-25
IL259846A (en) 2018-07-31
AU2016370626B2 (en) 2020-08-20
MX2021000773A (es) 2022-07-19
CA3008774A1 (en) 2017-06-22
AU2016370626A1 (en) 2018-08-02
SG11201805149XA (en) 2018-07-30
JP2021178840A (ja) 2021-11-18
US12274685B2 (en) 2025-04-15
IL318963A (en) 2025-04-01
CN108697680A (zh) 2018-10-23
KR20200055154A (ko) 2020-05-20
JP2018537513A (ja) 2018-12-20
CN113230244A (zh) 2021-08-10
MX379262B (es) 2025-03-10
PH12018501279A1 (en) 2019-01-28
KR20180094516A (ko) 2018-08-23
BR112018012313A2 (pt) 2018-12-04
JP2023153863A (ja) 2023-10-18
KR20240052856A (ko) 2024-04-23
NZ783466A (en) 2025-05-30
US20190224154A1 (en) 2019-07-25
US20230106655A1 (en) 2023-04-06
NZ744323A (en) 2020-08-28
RU2018126361A3 (es) 2020-01-22
WO2017103671A1 (en) 2017-06-22
RU2737089C2 (ru) 2020-11-24
EP4218736A2 (en) 2023-08-02
NZ766360A (en) 2025-05-30

Similar Documents

Publication Publication Date Title
MX2018007390A (es) Composiciones que comprenden acido 15-hidroxi eicosapentaenoico (15-hepe) y metodos de uso del mismo.
CL2019000609A1 (es) Variantes de alfa-glucosidasa ácida y usos de las mismas.
MX2022009148A (es) Composiciones y metodos para el tratamiento de hemoglobinopatias.
ECSP17029371A (es) Dihidropirrolopiridinas inhibidoras de ror-gamma
EP3388004A4 (en) Treatment instrument
MX373103B (es) Ciclopropilaminas como inhibidores de desmetilasa específica de lisina 1 (lsd1).
MX375352B (es) Reguladores de nrf2.
EP3509581A4 (en) FORMULATIONS OF (R
EP3263132C0 (en) Composition for treating il-6-related diseases
CL2019000610A1 (es) Variantes de alfa-glucosidasa ácida y usos de las mismas.
BR112017005266A2 (pt) inibidores de mk2 e uso dos mesmos
PL3277270T3 (pl) Kompozycje i sposoby leczenia niedokrwistości
MX2017001279A (es) Usos y composiciones de la flagelina.
EA201691610A8 (ru) Анти-jagged1 антитела и способы применения
EP3360010A4 (en) BI PHOTONS WITH VOTABLE SOURCE
AU2015287674B2 (en) Topical antiviral compositions and methods of using the same
MX389447B (es) Composiciones y métodos para anticuerpos dirigidos a bmp6.
PT3223827T (pt) Composição de fibras alimentares
MX2016009590A (es) Composiciones de apilimod y métodos para usar las mismas.
UY36500A (es) Composiciones del inhibidor de la nitrificación y métodos de preparación de las mismas
BR112018002382A8 (pt) Novos anticorpos anti-gvpi humano e usos dos mesmos
BR112017016562A2 (pt) métodos de produção de composições líquidas
MX2016012784A (es) Composiciones farmaceuticas solidas que comprenden derivados de biopterina y usos de tales composiciones.
CR20160448A (es) Nuevos derivados de piridina
EP3283115C0 (en) COMPOSITIONS FOR THE TREATMENT OF AUTISM